Factory output grew only 3.4 percent in September from a year earlier, a sharp slowdown from 15.4 percent in August and the weakest reading since August 2025, according to Trading Economics. For anyone who works in, supplies or invests in Singapore’s factories, the question is whether this is a blip or a turn.
In this article, we will discuss which clusters slowed, why biomedical production moved so much, how a strong business survey can sit beside weaker output, and what workers and manufacturers can sensibly do next.
Output in September at a Glance
Manufacturing output rose 3.4 percent year on year in September 2026, down from 15.4 percent in August, according to a Trading Economics report on Economic Development Board data published on 26 October 2026. By simple arithmetic, the pace of growth fell by 12.0 percentage points in a single month. The report describes the September reading as the lowest since August 2025, so this is a slowdown to a level not seen for about a year, not a fall to an all-time low.
Output also did not simply slow in year-on-year terms. On a seasonally adjusted basis, production fell 3.9 percent from August, the steepest monthly fall since June, with August itself revised to a fall of 1 percent. Year-on-year figures compare September with the same month a year earlier, while seasonally adjusted month-on-month figures compare September with the month just before after smoothing out regular calendar patterns. The two measures answer different questions, and here they point the same way, which is why the slowdown deserves attention even though growth is still positive.
For perspective, output in the first nine months of 2026 was up 9.8 percent, according to the same report. That means the year as a whole has been strong, and one weak month has not erased it. Readers who see only the latest figure can get the impression that factories have stalled, when the larger picture is of a strong run that hit a patch of softer output.
It is worth remembering that these figures are early estimates. Monthly manufacturing data are routinely revised, as the August figure for seasonally adjusted output was in this very report, and the cluster numbers can move as more complete information arrives. A sensible reader treats the first reading of any month as a good draft, and looks again when the next release revises it.
The table below sets out the cluster readings from the report, with the August figure beside each for comparison.
| Cluster | September 2026 (year on year) | August 2026 (year on year) |
| All manufacturing | Up 3.4 percent | Up 15.4 percent |
| Electronics | Up 5.7 percent | Up 28.3 percent |
| Of which semiconductors | Up 1.9 percent | Up 25.9 percent |
| Of which infocomms and consumer electronics | Up 29 percent | Up 66.3 percent |
| Precision engineering | Up 31 percent | Up 33 percent |
| Biomedical manufacturing | Down 32.8 percent | Up 2.3 percent |
| Transport engineering | Up 10.6 percent | Up 9.5 percent |
| General manufacturing | Up 4 percent | Up 1.6 percent |
| Chemicals | Down 4.6 percent | Down 12.8 percent |
Biomedical Manufacturing Drove the Drop
A Swing From Growth to Steep Decline
The biggest single change in the table is biomedical manufacturing, which went from growth of 2.3 percent in August to a fall of 32.8 percent in September. By simple arithmetic that is a swing of 35.1 percentage points in one month, far larger than the movement in any other cluster. When one cluster moves that far, it can pull the headline figure down even if most of the others keep growing.
Biomedical manufacturing covers pharmaceuticals and medical technology, and it is a major part of Singapore’s industrial base. Its monthly output tends to be uneven, so large moves in either direction are not unusual. A reading this weak is still a sizeable event, which is why it features so prominently in the reporting on the month.
What the Pharmaceutical Figure Shows
A summary on the news aggregator Digg, citing The Straits Times and The Business Times, adds more detail. According to that summary, pharmaceuticals within biomedical manufacturing fell 65.9 percent, and output excluding biomedical rose 9 percent. These two figures come from one secondary summary rather than from the main report, so treat them as reported, not confirmed.
If they are right, the story is clear. By simple arithmetic, the all-manufacturing figure of 3.4 percent sits 5.6 percentage points below the 9 percent for everything except biomedical, and the pharmaceutical fall of 65.9 percent means that pharmaceutical output was roughly a third of its level a year earlier. In plain terms, most of the slowdown came from one part of one cluster, and the rest of the sector was still growing at a respectable pace.
A fair question is how much weight a household should give a number like this. The answer is not much on its own. A drop in pharmaceutical output does not mean fewer medicines on pharmacy shelves in Singapore, since much of what the sector makes is sold abroad, and nothing in the reports quoted suggests any effect on local supplies or prices. It is a statement about factory production, and it matters mainly to the firms, workers and suppliers in that part of industry.
Why Pharmaceutical Output Swings so Much
The reports quoted here do not explain the fall, and this article will not invent a cause. It is possible to say, in general terms, why pharmaceutical output is lumpy. Drugs are often made in batches or campaigns, so a plant may produce a large run in one month and little in the next. Product mixes shift as medicines enter or leave the market, and plants shut down for maintenance or upgrades on schedules that do not follow the calendar.
Here is an illustration with invented round numbers. Imagine a plant that makes a batch worth S$40 million every second month and nothing in between. Its output is S$40 million in one month and zero in the next, so a comparison with the same month a year earlier can show a large jump or a large collapse purely because the batches fell in different months. Real plants are more complicated, but the logic helps explain why single months of pharmaceutical data can be misleading.
Electronics Cooled but Did Not Collapse
Electronics output rose 5.7 percent in September, down from 28.3 percent in August. That is a large deceleration, but it is still growth, and it is the second part of the story after biomedical. The cluster covers both semiconductors and the broader group of infocomms and consumer electronics, and the two moved very differently.
Semiconductors
Semiconductor output rose 1.9 percent, compared with 25.9 percent in August. That is close to flat. A reading like this can reflect a high base from a year earlier, changes in the product mix, the timing of orders or a pause in production, and the report does not say which. What it does show is that a part of the economy that had grown very fast in August had a much quieter month.
It would be a mistake to read one month of near-flat chip output as a reversal. Semiconductor production runs on long planning cycles, with capital equipment, qualification periods and customer contracts that do not change from month to month. Month-to-month wobbles are normal, and the information is in the trend over several months, not in a single reading.
Infocomms and Consumer Electronics
Infocomms and consumer electronics rose 29 percent, down from 66.3 percent. That is still a strong increase, even if it is less than half the August pace. In other words, this part of electronics slowed sharply and remained strongly positive, while the semiconductor part nearly stalled. The overall electronics figure of 5.7 percent sits between the two sub-group readings and much closer to the semiconductor one, which hints that semiconductors and other electronics categories carry more weight in the cluster than infocomms and consumer electronics do. The weights are not given in the report, so this is an inference and not a finding.
Readers should be wary of reading too much into any single cluster. Electronics is a big and varied group, and a headline for the cluster can hide very different stories inside it.
Other Clusters Tell a Steadier Story
Outside biomedical and electronics, the picture was calmer. Precision engineering rose 31 percent, almost unchanged from 33 percent in August, which suggests steady demand for the equipment and components the cluster supplies. Transport engineering rose 10.6 percent, slightly faster than 9.5 percent the month before. This cluster covers items such as aerospace-related work and marine and offshore activity in general terms, so its steady growth reflects different customers and different cycles from electronics.
General manufacturing rose 4 percent, up from 1.6 percent, which is a modest improvement from a low base. Chemicals fell 4.6 percent, still negative but better than the 12.8 percent fall in August. None of these is dramatic, and together they show that the slowdown was concentrated rather than broad. If every cluster had slowed by a similar amount, the message would be about weak demand across the board. Instead, the data suggest that two clusters did most of the damage, and others held up or improved.
Chemicals offer a quieter lesson in how to read recovery. A fall of 4.6 percent is a decline, yet it follows a fall of 12.8 percent, so the direction of change is improvement. Readers who look only at the sign of a number can miss the direction, and analysts usually pay as much attention to whether a weak cluster is getting better or worse as to whether it is above or below zero.
The precision engineering figure deserves a second look. Growth of 31 percent is strong by any standard, and it has barely changed month to month. That kind of consistency often signals contracts or long-running orders rather than a one-off spike. It does not guarantee the pattern will continue, but it is a more stable signal than the swings in biomedical and semiconductors.
Surveys Paint a Stronger Picture Than Output
What the PMI Measures
The S and P Global Singapore private-sector Purchasing Managers’ Index came in at 58.1 in September, down from 59.4 in August, which Malay Mail reported as a survey record. A reading above 50 signals expansion, so a score in the high 50s points to a business community reporting growth at a healthy pace. Singapore’s PMI is compiled from questionnaires sent to purchasing managers, who are asked whether things such as new orders, output, employment and purchasing are higher, lower or unchanged from the month before.
The distinction matters. A PMI is a diffusion index, which means it captures how many firms say activity went up, not how many units they made or by how much. It is also a survey of the private sector, so readers should check the survey’s own description to see how far it covers manufacturing versus services. A high PMI shows that most of the firms in the panel are reporting improvement, while an output index shows what happened to production in physical or value terms.
Reading the Gap
It is entirely possible for both to be right at once. The output index in September was weighed down by a large fall in one cluster, biomedical, which would not necessarily show up as a deterioration in a survey of purchasing managers across many industries. If most firms are reporting more orders and more activity, the PMI will stay high even when a handful of big producers have a poor month in value terms.
Consider a simple illustration with invented round numbers. Suppose ten firms answer a survey and eight say that their activity rose, while a single large producer, worth as much as the other nine combined in output terms, cut production sharply. The survey would show a clear majority reporting growth, and the output total could still fall. The survey counts firms, while the output index weighs them by size, and that difference alone can open a gap between the two.
That is why the two measures should be read as complements rather than rivals. Output tells you what was produced, according to the Economic Development Board data. The PMI tells you how firms feel about their trading conditions. When they diverge, the sensible question is which parts of the economy explain the gap, and the biomedical figures give a likely answer, though not a proven one.
Costs and the Inflation Warning
The S and P Global statement carried a caution. Firms kept raising purchases and staffing despite sharply higher purchase costs and wages. Jingyi Pan of S and P Global Market Intelligence said that September’s PMI data revealed that demand remained robust, and warned that continued expansion combined with worsening supplier performance from supply and shipping constraints could keep inflation elevated.
That is an important qualification for readers who think a strong factory survey is simply good news. Strong demand colliding with slower deliveries tends to push up prices, and firms may pass those costs on. The warning is a forecast of risk and not a measurement, but it fits the picture of a manufacturing sector that is busy and under cost pressure at the same time.
Workers Should Read One Cluster With Care
If You Work in Biomedical Manufacturing
A steep fall in monthly output in your cluster is naturally unsettling, but it does not by itself tell you anything about your job. Output can fall because of batch timing, planned maintenance or changes in the product mix, and companies often retain skilled staff through such swings because rehiring and retraining are expensive. The reports quoted here say nothing about hiring, layoffs or wages in biomedical manufacturing, so there is no basis in this material for concluding that jobs are at risk.
That said, a sensible worker keeps some habits in good times and bad. Keep your CV up to date, keep a savings buffer that covers a few months of expenses, and talk to your manager or HR if you have concerns about your team’s workload. Workforce Singapore offers career services, and SkillsFuture can help with training, though eligibility and funding rules change, so check with the relevant agencies for the current position.
Employers have a part to play as well. When output swings, the firms that handle it best tell staff early what they know and what they do not, use flexible measures such as training time and shift adjustments before considering job cuts, and give managers clear guidance on how to talk to teams. Workers can fairly ask about the outlook for their team and what support exists for upskilling, and a good employer will take the question seriously.
If You Work Elsewhere in Manufacturing
For workers in clusters that grew, such as precision engineering or infocomms and consumer electronics, the data are encouraging, but a strong month does not guarantee strong prospects. Pay and hiring depend on the firm’s own orders, margins and plans. The monthly manufacturing figures should be seen as background, and not as a prediction about your employer.
It is worth knowing the basics of the system should a job ever be at risk. Employers are generally required to notify the Ministry of Manpower of retrenchments, and the terms of any retrenchment benefit depend on your contract and length of service, so check your employment contract and the Ministry of Manpower’s guidance. If you are told your role is being affected, ask for the details in writing and seek advice from your union, if you belong to one, or the ministry’s resources.
Manufacturers and Suppliers Can Use the Gap to Plan
Inside the Factory
A manufacturer should resist the urge to extrapolate from one month, whether good or bad. If your own order book is healthy, a sector-wide dip driven by another cluster should not change your plans. If your products are tied to the cluster that slowed, check whether your customers are cutting orders or just rescheduling them. The difference between a pause and a decline is large, and the first calls for patience while the second calls for adjustment.
Inventory and scheduling are the practical levers. Production schedules that assume continued double-digit growth can leave you with unsold stock if demand moves, while schedules that are too cautious can leave you short when orders arrive. A rolling three-month forecast, reviewed monthly with your sales team and key customers, is a reasonable compromise. Keep a close eye on input costs too, since the survey warning suggests that supplier delays and higher prices may persist.
Pricing is the last practical point. If your costs for materials, freight or labour are rising, as the survey commentary suggests they are for many firms, review your quotations more often than usual and be clear with customers about how long a price holds. Absorbing every increase quietly is the quickest way to turn a busy year into a thin-margin one.
Along the Supply Chain
Suppliers to the larger plants feel these swings first. If you provide components, packaging, logistics or maintenance services to biomedical producers, a quiet month at the customer can mean a quiet month for you. Ask your main customers about their production calendars so that a planned pause does not catch you by surprise, and negotiate payment terms that keep your cash flow safe when volumes move.
Spreading your customer base across clusters is the most durable protection. This month’s data show electronics, precision engineering and transport engineering moving in different directions, which is exactly why a mixed customer book is steadier than one that depends on a single sector. It is not always possible, but even a small increase in diversification can help when one customer has an uneven quarter.
Conclusion
Begin by putting the month in proportion. Output rose 3.4 percent in September, the first nine months were up 9.8 percent, and the biggest drag came from one cluster whose output is known for being lumpy. That is a more complicated and less alarming story than a headline about a slowdown might suggest. For households, this is not a reason to change budgets or career plans.
Next, look at the next release before drawing firm conclusions. If biomedical output rebounds, September will look like a timing issue. If it stays weak, then the story becomes one of a more lasting shift, and that would deserve closer attention. The same goes for electronics, where the question is whether the cooling in semiconductors continues or reverses. Look at the seasonally adjusted month-on-month figures alongside the year-on-year ones, since they give a cleaner reading of direction. If the monthly fall of 3.9 percent is followed by a partial recovery, the picture will look quite different from one in which the fall deepens.
For households that follow the economy closely, a useful habit is to note which clusters are moving rather than only the total. A rise in the total driven by one cluster, or a fall driven by one cluster, tells a very different story from a broad shift, and that distinction is what separates a careful reader from one who reacts to headlines.
Finally, keep the three measures apart. Output measures production. Exports measure what is sold abroad, and survey indices such as the PMI measure how firms say conditions feel. All three can disagree for good reasons, and any one of them on its own is a partial view. For business owners, that means checking orders, costs and cash and not relying on a single headline. For workers, it means keeping skills and finances in good shape, whatever the monthly figures say.
Frequently Asked Questions
1. How Much Did Singapore’s Manufacturing Output Grow in September 2026?
According to Trading Economics, output rose 3.4 percent year on year, down from 15.4 percent in August. It was the lowest reading since August 2025. Seasonally adjusted output fell 3.9 percent from the previous month.
2. Which Sector Pulled Manufacturing Output Down in September?
Biomedical manufacturing, which fell 32.8 percent year on year after rising 2.3 percent in August. A summary citing The Straits Times and The Business Times says pharmaceuticals within it fell 65.9 percent. That second figure comes from a single secondary summary.
3. Is a 3.4 Percent Rise a Sign That Manufacturing Is in Trouble?
Not on its own. Output is still growing, the first nine months of 2026 were up 9.8 percent, and the weakness was concentrated in one cluster. One month of data, especially in a lumpy sector, is not a trend.
4. Does a Strong PMI Mean Factory Output Is Rising?
Not necessarily. The PMI is a survey of how firms say conditions have changed, while the output index measures production. The two can differ, as they did in September, when the PMI was 58.1 and output slowed.
5. Should I Worry About My Job if I Work in Pharmaceuticals?
The reports do not say anything about jobs, so a slowdown in monthly output is not by itself a reason to worry. It is sensible to keep your CV current and to speak to your employer if you have concerns. Check with the Ministry of Manpower and Workforce Singapore for current guidance.
6. When Is the Next Manufacturing Output Release?
The Economic Development Board publishes monthly figures, and the latest report was published on 26 October 2026. The next one is usually due around the same time the following month. Check the agency’s calendar to confirm the date.
